Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with heart failure where the heart's pumping function is relatively preserved (the left side of the heart squeezes out at least 55% of its blood with each beat), confirmed by a test done within the last year.
- People whose heart failure symptoms fall within a mild-to-moderate range, rated as Class I, II, or III on a standard medical scale (meaning symptoms range from none during everyday activity up to being comfortable only at rest).
- People who have been on a stable, guideline-recommended heart failure medication plan for at least one month (water/fluid pills may be an exception), including consideration of a class of medication called SGLT2 inhibitors.
- People whose heart's end-of-fill volume (how much blood is in the heart just before it pumps), adjusted for body size, is within a specific range measured by imaging.
- People whose heart shows a particular structural pattern — either thickened walls or an increased ratio of wall thickness to chamber size — confirmed by at least one specific heart imaging measurement (confirm exact measurements with trial site).
Who may not be able to join:
- People who are unable or unwilling to have a contrast MRI scan.
- People who have a standard medical indication for a permanent pacemaker, unless the reason is a specific condition where the heart does not speed up appropriately during exercise.
- People who currently have a persistent or permanent irregular heart rhythm called atrial fibrillation.
- People who have a heart structural problem that needs a medical procedure to fix it.
- People who had a heart valve replacement procedure less than 12 months before joining the trial.
- People with known stiffening around the heart sac, an inherited condition causing heart muscle thickening, or a disease where abnormal material builds up in the heart muscle.
- People with severe disease of the aortic or mitral heart valve (either significant leaking or a very narrowed valve opening).
- People who experience chest pain (angina) during physical activity.
- People with severe lung disease, including severe COPD — for example, those who need home oxygen, ongoing nebuliser treatment, long-term oral steroid treatment, or who were hospitalised for a lung-related flare-up within the past 12 months.
- People whose kidneys are functioning below a specific level, measured by a standard formula used to estimate kidney filtration rate.
- People whose blood pressure is not well controlled and falls outside the range of 100 to 160 mmHg (top number) even while taking blood pressure medication.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 763-526-2817
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
characterize the effect of TRT + PLR on cardiac structure. LV mass, LVEDV, LVESV, and wall thickness which will be collected at baseline, 3-month, 6-month, 9-month, and 12-month visits.; Characterize the effect of pacing therapies on health status, defined as change in the Minnesota Living with Heart Failure Questionnaire (MLHFQ) from baseline to 3, 6, and 9 months.; Characterize the durability of cardiac remodeling changes and assess the safety and tolerability of TRT + PLR.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.